Amylin CEO on Diabetes & Diet Drugs

Previous Video: What CIT Bankruptcy Means for Small Biz
Next Video: RBS, Lloyds Face Restructuring

Airtime: ET

The FDA has approved Amylin's Byetta as a stand-alone diabetes drug. The company's CEO, Daniel Bradbury, discusses the approval and more with CNBC's Mike Huckman.

Previous Video: What CIT Bankruptcy Means for Small Biz
Next Video: RBS, Lloyds Face Restructuring

TOP VIDEO

NABE Outlook
The National Association of Business Economics upgrades its own economic forecasts, with CNBC's Steve Liesman, Becky Quick & Joe Kernen.

Market Task Force

A Monday morning strategy session for the first trading day of the holiday week, with Lou Brien, DRW Trading Group strategist; Mark Vitner, Wells Fargo Advisors sr. equity market strategist; and CNBC's Becky Quick & Joe Kernen.

LATEST VIDEO

- Earnings Central: HPQ
  A preview of the earnings announcements for the day, including HP, with Jayson Noland, Robert W. Baird sr. analyst and Mark Stahlman, Signal Lake Ventures technology strategist.
- Five-Star Investing: James Reynolds
  A cautiously optimistic outlook and a prediction for recovery in the world markets, with James Reynolds, Loop Capital Markets chairman & CEO.

Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc. All Rights Reserved.
A Division of NBC Universal

Amylin CEO on Diabetes & Diet Drugs

More Videos from CNBC

TOP VIDEO

LATEST VIDEO